HYTERA
21.4.2022 14:20:12 CEST | Business Wire | Press release
Hytera (SZSE: 002583), the leading global provider of professional communications technologies and solutions, has released its annual Corporate Responsibility Report recently, summarizing the company’s environmental, social and governance (ESG) performance in 2021.
As a leading player in the Professional Mobile Radio (PMR) industry, Hytera has a long history of providing stakeholders with transparent information on its annual sales and ESG performance. The report features successes achieved last year, including its performance on business development as well as environmental sustainability, as well as technical support for public events and disaster relief around the world.
Continuous Innovation to Lead the Industry Transformation
Hytera is focused on technological innovation to drive business development. By the end of 2021, Hytera's total R&D investment had increased to USD 162 million, accounting for 18.05% of the sales revenue, and R&D personnel accounted for over 40% of the staff. Hytera has filed for 2,892 patents in total, including 507 PCT patents, 291 overseas patents, and 79 5G and LEO satellites patents; the overall patent licensing rate has reached 93.32%.
Hytera’s PMR-LTE convergent solutions have been recognized by the market in the past few years and so far, Hytera has deployed more than 200 converged multi-media PTT platforms globally and has been cooperating with over 20 local operators to better serve more vertical industry uses. In 2021, the International Critical Communications Awards (ICAA) awarded Hytera the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC customer case using PMR-LTE convergent solutions.
Better Operation for Environmental Sustainability
Hytera is dedicated to operating with sustainable business practices, including energy saving, emission reduction, and green and recyclable product manufacturing management. In 2021, Hytera’s electricity consumption decreased by 25% YOY, and general industrial waste dropped by 22% YOY.
In 2021, Hytera's subsidiaries HMF and Teltronic have organized multiple Green Travel campaigns, which reduced 809 kg of carbon dioxide emissions, exhaust gas and noise pollution by bike cycling instead of car driving in commutes to work.
Participation in Social Activities and Community Service to Repay the Society
Hytera has actively contributed its capabilities to improve disease prevention, for example, donating two-way radios to staff in hospitals, medical teams and security departments around the world in order to combat COVID-19.
Hytera also actively participated in various social welfare activities. In late 2021, Hytera supported Tinzert Elementary School of Morocco with a donation of warm coats and medical masks, and renovated the school to withstand the coldness of the mountainous area. Besides, Hytera was recognized as the science and technology education center and set up technology tutorials for both students and adults utilizing the PMR technologies and devices.
In terms of disaster relief, Hytera provided professional communication supports to the local rescue teams for flood relief in Henan China, and western Germany. Hytera also provided support to Blue Sky Rescue (BSR) volunteers in Europe to empower their post-disaster rescue work.
This year, the world faced greater global challenges than ever before, necessitating the use of professional technologies and products. Hytera’s innovations in communications technologies are revolutionizing industries and addressing some of the society's serious challenges.
Hytera is proud of its efforts to protect the environment and keep the community safe, and everything it does is guided by the code of ethics and business conduct.
Hytera will continue to make contributions to the people, communities, and the environment in order to make the world more intelligently connected and to help shape a better future for everybody.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005570/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom